A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
News|Articles|February 9, 2024
AJMC® in the Press, February 9, 2024
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Articles in
A piece by
Advertisement
Related to this article
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.
Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.
Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.
The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Cap Eases Patient Costs as Negotiation Squeezes Practices
2
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
3
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
4
PBM Satisfaction Stalls as Net Promoter Score Turns Negative
5